Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Oct 25;406(10514):2017-2032.
doi: 10.1016/S0140-6736(25)01436-9. Epub 2025 Sep 9.

Large-vessel vasculitis

Affiliations
Review

Large-vessel vasculitis

Patrice Cacoub et al. Lancet. .

Abstract

Primary large-vessel vasculitis encompasses conditions that, despite sharing many common features, constitute distinct entities that have their own prognostic implications. These conditions include giant cell arteritis and Takayasu arteritis, with isolated aortitis being increasingly recognised in the literature and studied within this disease spectrum. Epidemiological studies have evidenced a worldwide distribution of Takayasu arteritis. In giant cell arteritis, distinct clinical phenotypes with specific outcomes (ie, cranial and large vessel forms) have been recognised. The advancements that have been made in vascular imaging have enabled improvement in diagnosis and classification of these diseases, although their value in follow-up continues to be assessed. Targeted therapies that can induce clinical remission with reduced glucocorticoid exposure are emerging. However, many patients develop vascular damage over time, highlighting the need for further understanding of the pathophysiological link between inflammation, vascular injury, and remodelling.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests CAL declares research funding from Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, and NS Pharma; and is a non-paid consultant for Bristol-Myers, AbbVie, and AstraZeneca. ZTM declares research funding and having consulted for Novartis, AstraZeneca, Abbvie, and Janssen. DS declares research funding and consulting for Novartis, Abbvie, Janssen, Fresenius, Roche-Chugai, and GlaxoSmithKline. All other authors declare no competing interests.

MeSH terms

Substances

LinkOut - more resources